Personalized & Precise
Next generation cancer-targeted radiopharmaceuticals
Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar is building a drug development pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical experience to help reduce the risk and accelerate the clinical development of its drug product candidates.
Monopar's team is located in San Francisco, CA and Chicago, IL.
Licensing, developing and commercializing transformative oncology therapeutics
Multiple factors drive our passion for oncology
Monopar’s pipeline consists of Phase 1-stage MNPR-101-Zr for imaging advanced cancers and late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for the treatment of advanced cancers.
Product | Indications | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
---|---|---|---|---|---|---|---|
MNPR-101-Zr |
Imaging Agent for MNPR-101 RIT |
Discovery complete |
Preclinical complete |
Phase 1 in progress |
Phase 2 not started |
Phase 3 not started |
Phase 1 Clinical Trial Active and Recruiting |
MNPR-101 RIT |
Advanced Solid Cancers |
Discovery complete |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Late Preclinical |
Early Pipeline |
Solid cancers |
Discovery complete |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Early Preclinical |
Early Pipeline |
Solid cancers |
Discovery in progress |
Preclinical not started |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Discovery |